Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome

Rifaximin, a non-systemic antibiotic, is efficacious for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). Given the emerging association between the gut microbiota and IBS, this study examined potential effects of rifaximin on the gastrointestinal microbial community in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Fodor, Anthony A., Pimentel, Mark, Chey, William D., Lembo, Anthony, Golden, Pamela L., Israel, Robert J., Carroll, Ian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper/Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363070/
https://www.ncbi.nlm.nih.gov/pubmed/29708822
http://dx.doi.org/10.1080/19490976.2018.1460013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363070/
https://www.ncbi.nlm.nih.gov/pubmed/29708822
http://dx.doi.org/10.1080/19490976.2018.1460013

Ejemplares similares